The angle is getting nasty, so whilst its below $9.72 look lower, i see nothing to suggest a major low in place.Short term it can bounce to around $8,50, but i suspect any bounces will be sold into.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%